Repligen (NASDAQ:RGEN) Updates FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.420-1.490 for the period, compared to the consensus earnings per share estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million. Repligen also updated its FY24 guidance to $1.42-1.49 EPS.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on RGEN shares. KeyCorp increased their price target on Repligen from $210.00 to $220.00 and gave the stock an overweight rating in a report on Thursday, February 15th. JPMorgan Chase & Co. dropped their target price on Repligen from $230.00 to $200.00 and set an overweight rating for the company in a research report on Thursday. Finally, Stifel Nicolaus increased their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a buy rating in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $197.75.

Repligen Stock Up 0.4 %

Shares of RGEN traded up $0.74 during mid-day trading on Friday, reaching $167.05. The company’s stock had a trading volume of 454,984 shares, compared to its average volume of 538,521. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.75. Repligen has a 12-month low of $110.45 and a 12-month high of $211.13. The stock has a market cap of $9.33 billion, a PE ratio of 668.23, a price-to-earnings-growth ratio of 5.44 and a beta of 1.03. The company’s 50 day moving average is $180.81 and its 200 day moving average is $174.09.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company had revenue of $151.31 million during the quarter, compared to analysts’ expectations of $150.06 million. During the same quarter in the prior year, the company earned $0.64 earnings per share. The business’s revenue for the quarter was down 17.1% on a year-over-year basis. Equities analysts anticipate that Repligen will post 1.46 EPS for the current fiscal year.

Insider Transactions at Repligen

In other news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Anthony Hunt sold 16,707 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 25,597 shares of company stock worth $5,039,532. Corporate insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.